All News

The 2014 Pharmaceutical Price Regulation Scheme (PPRS), the voluntary agreement to cover pricing of branded medicines supplied to the NHS in the UK, included provisions for member companies to pay back to the Department of Health (DH) if spend went over pre-agreed growth rates.

After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover?

The Cancer Drugs Fund (CDF) is a particular English approach to deal with rejections by the National Institute for Health and Care Excellence (NICE) for new cancer medicines.

An illustrious panel of investment professionals spoke optimistically on the orphan disease space in spite of concerns surrounding escalating drug prices in specialty pharmaceuticals.

The recent termination of AbbVie’s deal to acquire Shire has “jolted the industry out of its reverie” by becoming pharma’s first major casualty of new US tax inversion legislation, says research and consulting firm GlobalData.

Exits from the CMO industry are a more recent development that seems to be picking up momentum.

This month’s special issue of Pharm Exec Global Digest looks at..

After almost two years of anticipation, Janet Woodcock, director of the Center for Drug Evaluation and Research, has administration approval for organizational changes to bolster programs and policies to ensure drug quality.

It’s fall and the 2015 Obamacare Exchange Rx insurance offerings will be presented to patients on November 15th. But at this point, what insights do American Rx brand managers and marketers actually have on the results of the Obamacare Rx experience in 2014?

In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more…

To understand just how far mobile and digital technology can truly influence progress in global healthcare, we first need to form the foundation of the discussion with a few rudimentary facts.

You would expect that, given a physician shortage, my goal of getting back into obstetrics would be supported and even welcomed.

On September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy.

The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets.

After a change in distribution strategy at Genentech, Ascension Health has prohibited sales representatives from the drug maker to solicit physicians at Ascension’s 1900 sites of care around the country.

Thirty-nine years ago this past June, an article appeared in BusinessWeek that offered readers what was for its time a startling degree of foresight.

Researchers at the Massachusetts Institute of Technology (MIT) have devised a novel drug capsule coated with tiny needles to deliver large-molecule biopharmaceuticals.

With more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before.

Lurking in the shadows of the US General Elections is something called The Sequestration Transparency Act of 2011.

Companies gain support-and pressure-to deliver new treatments for spreading outbreak.

Pharmaceutical professionals, teams, and organizations can succeed at an elite level by tackling the tough mental challenges of Navy SEAL training.

An escalating political debate over pharma pricing and reimbursement nears the boiling point.

In the wake of last week’s declaration by new HHS Secretary, Sylvia Burwell, that “Obamacare is working”, it’s probably time for American Rx product managers and marketers to step back and consider where we have travelled since January 1st of this year.

In a bit of good news for pharma, Moody’s Investors Service has upgraded its outlook for the global pharmaceutical industry to stable.

Successfully commercializing a proprietary drug in China can be a Kafkaesque affair.

The UK’s Medicines and Healthcare Regulatory Authority (MHRA) has awarded Northwest Biotherapeutics, Inc. (Bethesda, MD) the very first “Promising Innovative Medicine”, or PIM designation, for the company’s DCVax-L product.

This month’s ePatient Connections Summit in Philadelphia, PA, saw biopharmaceutical firms, medical device companies, and patient advocates discuss best practices for engaging patients online and in social media settings.

FDA’s Center for Drug Evaluation and Research is establishing an Emerging Technology Team (ETT) to assist innovative manufacturers in navigating the regulatory process and “overcoming roadblocks”.